ReviewMelanoma management2015
Pharmacist's role in optimizing therapy of the newer agents for the treatment of metastatic melanoma.
Review in Melanoma management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data.Clinical pharmacology and therapeutics · 2026Article
- Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies.Melanoma management · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic melanoma is a disease with a historically dismal survival of 6-9 months with treatment. It is considered an incurable disease and resistant to conventional chemotherapy. We have learned much about the role of newer targets in the development of melanoma which has helped us in developing targeted therapy and improving immunotherapy for the treatment of melanoma. These new therapies have a different adverse event profile from conventional chemotherapy. We will define these and their management from the perspective of the oncology pharmacist. We will also discuss the role that the oncology pharmacist can play in optimizing therapy and side effect management in the multidisciplinary team treating patients that have unresectable or metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.